Search

Author/Creator Storek, Michael

1. First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor. Issue 4 (2nd February 2023)

Authors:
Chow, Timothy; Shamszad, Pirouz; Vinnard, Christopher; Yoon, Esther; Belinski, Julia; Karpenko, Irene; Perrin, Laurent; Auwarter, Kristen; Storek, Michael; Surks, Howard; Wong, Nancy; Cohen, Yehuda Z.
Journal:
Clinical and translational science
Issue:
Volume 16:Issue 4(2023)
Page Start:
673
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models. (January 2019)

Authors:
Fridkis-Hareli, Masha; Storek, Michael; Or, Eran; Altman, Richard; Katti, Suresh; Sun, Fang; Peng, Tao; Hunter, Jeff; Johnson, Krista; Wang, Yi; Lundberg, Ante S.; Mehta, Gaurav; Banda, Nirmal K.; Michael Holers, V.
Journal:
Molecular immunology
Issue:
Volume 105(2019:Jan.)
Page Start:
150
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search